Startup profile · funding coverage
ai3Bio funding, valuation and investors
Autoimmune-disease biotech formed from complementary immunology platforms; launched with a $48 million Series A.
Keep track of ai3Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$48M · September 29, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$48M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a
Investors in latest funding
Lead: UPMC Enterprises , Ziff Capital Partners
Overview
ai3Bio launched in September 2026 by combining technology from Corner Therapeutics and University of Pittsburgh-backed Novasenta. The company announced $48 million in Series A funding led by UPMC Enterprises and Ziff Capital Partners to develop therapies that selectively target disease-driving immune cells.
Why ai3Bio is interesting
The company combines two research platforms and targets selective depletion of diseased T cells rather than broad immune suppression.
Key facts
- Sep 29, 2026: $48M Series A
- Company formed from Corner Therapeutics and Novasenta technology
Funding history (newest first)
Series A
2026-09-29 $48M- UPMC Enterprises (lead)
- Ziff Capital Partners (lead)
Source: https://www.fiercebiotech.com/biotech/ai3bio-emerging-stealth-take-gun-out-hands-immune-system
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.